Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CC312
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of CC312 for Relapsed/Refractory Autoimmune Diseases
Details : (CC312) is currently being evaluated in Phase I clinical studies for the treatment of Lupus Erythematosus, Systemic.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 26, 2025
Lead Product(s) : CC312
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CC312
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy Study of CC312 for Moderate to Severe SLE
Details : (CC312) is currently being evaluated in Phase I clinical studies for the treatment of Lupus Erythematosus, Systemic.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 17, 2025
Lead Product(s) : CC312
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CC312
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety Study of CC312 in Autoimmune Disease Patients
Details : CC312 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lupus Erythematosus, Systemic.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 21, 2025
Lead Product(s) : CC312
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CC312 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, Non-Hodgkin.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 14, 2023